| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Endometrium | 139 | 2021 | 180 | 21.960 |
Why?
|
| Endometriosis | 78 | 2020 | 99 | 13.540 |
Why?
|
| Embryo Implantation | 54 | 2021 | 58 | 9.540 |
Why?
|
| Infertility, Female | 32 | 2019 | 37 | 7.210 |
Why?
|
| Progesterone | 33 | 2019 | 101 | 3.670 |
Why?
|
| Integrins | 26 | 2010 | 41 | 2.990 |
Why?
|
| Uterine Diseases | 13 | 2019 | 22 | 2.990 |
Why?
|
| Pregnancy | 51 | 2020 | 997 | 2.950 |
Why?
|
| Luteal Phase | 17 | 2016 | 29 | 2.820 |
Why?
|
| Female | 192 | 2021 | 19959 | 2.570 |
Why?
|
| Fertilization in Vitro | 9 | 2018 | 22 | 2.510 |
Why?
|
| Menstrual Cycle | 35 | 2017 | 61 | 2.490 |
Why?
|
| Uterus | 25 | 2018 | 103 | 2.160 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 4 | 2019 | 6 | 1.990 |
Why?
|
| Humans | 183 | 2021 | 32005 | 1.900 |
Why?
|
| Endometrial Neoplasms | 16 | 2017 | 49 | 1.790 |
Why?
|
| Receptors, Progesterone | 21 | 2018 | 72 | 1.740 |
Why?
|
| Abortion, Habitual | 5 | 2018 | 5 | 1.720 |
Why?
|
| Polycystic Ovary Syndrome | 8 | 2011 | 20 | 1.660 |
Why?
|
| Adult | 88 | 2020 | 9345 | 1.620 |
Why?
|
| Integrin beta3 | 8 | 2017 | 11 | 1.480 |
Why?
|
| Embryo Transfer | 5 | 2019 | 10 | 1.380 |
Why?
|
| Estrogens | 12 | 2015 | 180 | 1.280 |
Why?
|
| Receptors, Vitronectin | 12 | 2002 | 13 | 1.270 |
Why?
|
| Immunohistochemistry | 37 | 2018 | 538 | 1.240 |
Why?
|
| Gene Expression Regulation | 19 | 2020 | 495 | 1.220 |
Why?
|
| Biopsy | 15 | 2017 | 259 | 1.130 |
Why?
|
| Gynecologic Surgical Procedures | 2 | 2018 | 47 | 1.120 |
Why?
|
| Chorionic Gonadotropin | 6 | 2016 | 13 | 1.090 |
Why?
|
| Animals | 53 | 2020 | 7541 | 1.050 |
Why?
|
| Stromal Cells | 17 | 2020 | 84 | 1.050 |
Why?
|
| Cell Adhesion Molecules | 6 | 2014 | 43 | 1.020 |
Why?
|
| Ovulation Induction | 4 | 2019 | 7 | 1.020 |
Why?
|
| Adenocarcinoma | 9 | 2015 | 308 | 0.990 |
Why?
|
| Laparoscopy | 7 | 2016 | 172 | 0.890 |
Why?
|
| Case-Control Studies | 20 | 2020 | 898 | 0.890 |
Why?
|
| Integrin alphaVbeta3 | 4 | 2014 | 7 | 0.850 |
Why?
|
| Clomiphene | 3 | 2011 | 4 | 0.830 |
Why?
|
| Estradiol | 17 | 2015 | 136 | 0.820 |
Why?
|
| Pelvic Pain | 4 | 2018 | 18 | 0.820 |
Why?
|
| Pregnancy Outcome | 4 | 2016 | 90 | 0.810 |
Why?
|
| Reproductive Techniques, Assisted | 3 | 2019 | 6 | 0.800 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2020 | 14 | 0.760 |
Why?
|
| Sirtuin 1 | 2 | 2020 | 38 | 0.740 |
Why?
|
| Inflammation | 8 | 2020 | 530 | 0.740 |
Why?
|
| MicroRNAs | 5 | 2019 | 180 | 0.740 |
Why?
|
| Surrogate Mothers | 1 | 2020 | 1 | 0.730 |
Why?
|
| Fertility | 8 | 2017 | 31 | 0.720 |
Why?
|
| Reproductive Control Agents | 2 | 2016 | 2 | 0.710 |
Why?
|
| Young Adult | 22 | 2020 | 2636 | 0.700 |
Why?
|
| Antigens, Neoplasm | 5 | 2014 | 45 | 0.700 |
Why?
|
| Prospective Studies | 17 | 2017 | 2282 | 0.670 |
Why?
|
| STAT3 Transcription Factor | 2 | 2016 | 25 | 0.670 |
Why?
|
| Ovarian Diseases | 1 | 2018 | 8 | 0.650 |
Why?
|
| Sialoglycoproteins | 6 | 2021 | 8 | 0.620 |
Why?
|
| Pregnancy Rate | 5 | 2019 | 11 | 0.620 |
Why?
|
| Complement System Proteins | 1 | 2017 | 9 | 0.600 |
Why?
|
| Epithelial Cells | 12 | 2021 | 141 | 0.600 |
Why?
|
| Embryo, Mammalian | 3 | 2007 | 31 | 0.580 |
Why?
|
| Leukemia Inhibitory Factor | 4 | 2018 | 6 | 0.570 |
Why?
|
| Mice | 21 | 2020 | 2484 | 0.560 |
Why?
|
| Protein Inhibitors of Activated STAT | 1 | 2016 | 3 | 0.550 |
Why?
|
| Neovascularization, Pathologic | 6 | 2019 | 82 | 0.540 |
Why?
|
| Papio | 10 | 2020 | 91 | 0.540 |
Why?
|
| RNA, Messenger | 17 | 2017 | 508 | 0.520 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 10 | 2013 | 160 | 0.510 |
Why?
|
| Cytokines | 10 | 2019 | 256 | 0.510 |
Why?
|
| Epidermal Growth Factor | 6 | 2004 | 27 | 0.510 |
Why?
|
| Staining and Labeling | 4 | 2012 | 60 | 0.500 |
Why?
|
| Luteinizing Hormone | 7 | 2014 | 22 | 0.500 |
Why?
|
| Keratin-19 | 1 | 2014 | 1 | 0.490 |
Why?
|
| Hydrocarbons, Fluorinated | 3 | 2020 | 4 | 0.490 |
Why?
|
| Signal Transduction | 13 | 2020 | 682 | 0.490 |
Why?
|
| Transcription Factors | 4 | 2020 | 181 | 0.490 |
Why?
|
| Pregnancy Complications | 1 | 2016 | 105 | 0.490 |
Why?
|
| Apoptosis | 5 | 2016 | 360 | 0.480 |
Why?
|
| Wine | 1 | 2014 | 2 | 0.470 |
Why?
|
| Phytoestrogens | 1 | 2014 | 23 | 0.470 |
Why?
|
| Stilbenes | 1 | 2014 | 23 | 0.460 |
Why?
|
| Estrogen Receptor alpha | 4 | 2014 | 52 | 0.460 |
Why?
|
| Pyrimidines | 3 | 2020 | 65 | 0.460 |
Why?
|
| Receptors, Estrogen | 8 | 2013 | 113 | 0.460 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 5 | 2010 | 105 | 0.460 |
Why?
|
| Ovulation | 2 | 2011 | 9 | 0.460 |
Why?
|
| Receptors, Androgen | 4 | 2007 | 47 | 0.450 |
Why?
|
| Homeostasis | 1 | 2014 | 132 | 0.450 |
Why?
|
| Estriol | 1 | 2013 | 4 | 0.440 |
Why?
|
| Lipoxins | 1 | 2013 | 2 | 0.440 |
Why?
|
| Methylene Blue | 1 | 2012 | 3 | 0.430 |
Why?
|
| Ovulation Prediction | 1 | 2012 | 1 | 0.430 |
Why?
|
| Middle Aged | 29 | 2020 | 11817 | 0.430 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 14 | 2014 | 263 | 0.430 |
Why?
|
| Infertility | 5 | 2002 | 19 | 0.420 |
Why?
|
| Transforming Growth Factor beta | 3 | 2002 | 64 | 0.420 |
Why?
|
| Interleukin-6 | 5 | 2020 | 247 | 0.420 |
Why?
|
| Adolescent | 18 | 2020 | 3539 | 0.420 |
Why?
|
| Contraception | 2 | 2003 | 13 | 0.420 |
Why?
|
| Models, Biological | 6 | 2016 | 392 | 0.410 |
Why?
|
| Glycoproteins | 7 | 2002 | 45 | 0.410 |
Why?
|
| Aromatase Inhibitors | 1 | 2012 | 9 | 0.400 |
Why?
|
| Nitriles | 1 | 2012 | 23 | 0.400 |
Why?
|
| Triazoles | 1 | 2012 | 14 | 0.400 |
Why?
|
| Gonadotropin-Releasing Hormone | 4 | 2019 | 10 | 0.400 |
Why?
|
| Cells, Cultured | 14 | 2020 | 833 | 0.400 |
Why?
|
| Endometrial Hyperplasia | 3 | 2009 | 14 | 0.390 |
Why?
|
| DNA-Binding Proteins | 3 | 2015 | 147 | 0.390 |
Why?
|
| Women's Health | 1 | 2013 | 235 | 0.390 |
Why?
|
| Steroids | 4 | 2006 | 38 | 0.390 |
Why?
|
| Epithelium | 9 | 2006 | 30 | 0.380 |
Why?
|
| Down-Regulation | 8 | 2017 | 142 | 0.380 |
Why?
|
| Ascitic Fluid | 5 | 2019 | 10 | 0.370 |
Why?
|
| Estrogen Receptor Modulators | 2 | 2008 | 25 | 0.370 |
Why?
|
| Mice, Knockout | 8 | 2018 | 443 | 0.360 |
Why?
|
| Cell Line, Tumor | 6 | 2017 | 726 | 0.350 |
Why?
|
| Gene Expression Profiling | 9 | 2018 | 322 | 0.350 |
Why?
|
| Membrane Proteins | 4 | 2017 | 256 | 0.350 |
Why?
|
| Anaphylatoxins | 1 | 2009 | 1 | 0.350 |
Why?
|
| Complement C3a | 1 | 2009 | 2 | 0.350 |
Why?
|
| Disease Models, Animal | 9 | 2019 | 1022 | 0.340 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2020 | 261 | 0.330 |
Why?
|
| Abortion, Spontaneous | 2 | 2019 | 12 | 0.330 |
Why?
|
| Hormones | 3 | 2007 | 22 | 0.330 |
Why?
|
| Decidua | 7 | 2019 | 18 | 0.330 |
Why?
|
| Prunella | 1 | 2008 | 1 | 0.330 |
Why?
|
| Tumor Cells, Cultured | 8 | 2008 | 170 | 0.320 |
Why?
|
| Drugs, Chinese Herbal | 1 | 2008 | 7 | 0.320 |
Why?
|
| Risk Factors | 6 | 2020 | 3876 | 0.320 |
Why?
|
| Fallopian Tube Diseases | 4 | 2007 | 8 | 0.320 |
Why?
|
| Live Birth | 2 | 2019 | 7 | 0.320 |
Why?
|
| Retrospective Studies | 9 | 2020 | 3509 | 0.320 |
Why?
|
| Disease Progression | 4 | 2020 | 594 | 0.310 |
Why?
|
| Mice, Inbred C57BL | 7 | 2019 | 767 | 0.310 |
Why?
|
| Dysmenorrhea | 2 | 2018 | 3 | 0.310 |
Why?
|
| Peritoneal Diseases | 2 | 2020 | 4 | 0.310 |
Why?
|
| Alkaline Phosphatase | 3 | 2014 | 38 | 0.300 |
Why?
|
| Genital Diseases, Female | 1 | 2007 | 5 | 0.300 |
Why?
|
| Receptor, Notch1 | 2 | 2020 | 8 | 0.300 |
Why?
|
| Immediate-Early Proteins | 1 | 2007 | 9 | 0.300 |
Why?
|
| Gene Expression | 5 | 2017 | 338 | 0.290 |
Why?
|
| Ovarian Neoplasms | 3 | 2020 | 96 | 0.290 |
Why?
|
| Diethylstilbestrol | 3 | 2014 | 4 | 0.290 |
Why?
|
| Killer Cells, Natural | 3 | 2014 | 25 | 0.290 |
Why?
|
| Osteopontin | 6 | 2009 | 10 | 0.290 |
Why?
|
| Estrogen Antagonists | 3 | 2017 | 17 | 0.290 |
Why?
|
| Cell Proliferation | 6 | 2019 | 604 | 0.280 |
Why?
|
| Treatment Outcome | 6 | 2018 | 3306 | 0.280 |
Why?
|
| Time Factors | 7 | 2018 | 2149 | 0.270 |
Why?
|
| Dose-Response Relationship, Drug | 7 | 2017 | 633 | 0.270 |
Why?
|
| Blotting, Northern | 7 | 2003 | 31 | 0.260 |
Why?
|
| Oligopeptides | 2 | 2003 | 45 | 0.260 |
Why?
|
| Pregnancy Proteins | 4 | 2002 | 13 | 0.260 |
Why?
|
| Oocyte Donation | 3 | 2001 | 3 | 0.250 |
Why?
|
| Mucin-4 | 2 | 2015 | 2 | 0.250 |
Why?
|
| Paracrine Communication | 3 | 2019 | 9 | 0.250 |
Why?
|
| Interferon-gamma | 3 | 2018 | 57 | 0.250 |
Why?
|
| Neoplasm Proteins | 3 | 2007 | 148 | 0.250 |
Why?
|
| Blotting, Western | 9 | 2014 | 289 | 0.250 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2005 | 34 | 0.240 |
Why?
|
| Cell Adhesion | 6 | 2016 | 108 | 0.240 |
Why?
|
| Telomerase | 2 | 2020 | 22 | 0.240 |
Why?
|
| Proteomics | 3 | 2019 | 94 | 0.240 |
Why?
|
| Reference Values | 8 | 2002 | 246 | 0.230 |
Why?
|
| Gonadotropins | 2 | 2005 | 5 | 0.230 |
Why?
|
| Placenta | 2 | 2002 | 74 | 0.220 |
Why?
|
| Cell Line | 7 | 2020 | 435 | 0.220 |
Why?
|
| Coculture Techniques | 3 | 2005 | 81 | 0.220 |
Why?
|
| Antigens, CD | 3 | 2000 | 103 | 0.220 |
Why?
|
| Cervix Uteri | 2 | 2001 | 28 | 0.210 |
Why?
|
| Cell Division | 3 | 2002 | 99 | 0.210 |
Why?
|
| Evidence-Based Medicine | 2 | 2017 | 217 | 0.210 |
Why?
|
| Nitric Oxide Synthase | 1 | 2002 | 35 | 0.210 |
Why?
|
| Gene Expression Regulation, Developmental | 2 | 2019 | 69 | 0.210 |
Why?
|
| Anovulation | 1 | 2002 | 5 | 0.210 |
Why?
|
| Transcription, Genetic | 4 | 2017 | 137 | 0.210 |
Why?
|
| Microscopy, Electron, Scanning | 3 | 2012 | 98 | 0.210 |
Why?
|
| Fertility Agents, Female | 3 | 2011 | 8 | 0.200 |
Why?
|
| Receptors, Aryl Hydrocarbon | 2 | 2014 | 8 | 0.200 |
Why?
|
| In Situ Hybridization | 6 | 2003 | 38 | 0.190 |
Why?
|
| Contraceptives, Postcoital | 1 | 2000 | 1 | 0.190 |
Why?
|
| Flutamide | 1 | 2000 | 5 | 0.190 |
Why?
|
| Cell Nucleus | 6 | 2018 | 108 | 0.190 |
Why?
|
| Macrophage Colony-Stimulating Factor | 1 | 2000 | 5 | 0.190 |
Why?
|
| Labor, Obstetric | 1 | 2001 | 36 | 0.190 |
Why?
|
| Up-Regulation | 6 | 2018 | 189 | 0.180 |
Why?
|
| Reproduction | 1 | 2020 | 15 | 0.180 |
Why?
|
| Galectins | 1 | 2020 | 6 | 0.180 |
Why?
|
| Immunoenzyme Techniques | 8 | 2014 | 52 | 0.180 |
Why?
|
| Trophoblasts | 2 | 2000 | 10 | 0.180 |
Why?
|
| Myometrium | 2 | 2018 | 11 | 0.170 |
Why?
|
| Endothelial Cells | 1 | 2021 | 189 | 0.170 |
Why?
|
| Reproducibility of Results | 5 | 2014 | 762 | 0.170 |
Why?
|
| Pre-Eclampsia | 1 | 2000 | 66 | 0.170 |
Why?
|
| Protein Binding | 3 | 2013 | 201 | 0.170 |
Why?
|
| Cystitis, Interstitial | 1 | 2020 | 45 | 0.170 |
Why?
|
| Receptors, Lymphocyte Homing | 2 | 1996 | 3 | 0.170 |
Why?
|
| Diagnostic Techniques, Obstetrical and Gynecological | 1 | 2019 | 1 | 0.170 |
Why?
|
| Homeodomain Proteins | 1 | 1999 | 51 | 0.170 |
Why?
|
| Cell Culture Techniques | 1 | 2020 | 173 | 0.170 |
Why?
|
| Oocytes | 2 | 2001 | 48 | 0.170 |
Why?
|
| Neutrophils | 1 | 2019 | 106 | 0.170 |
Why?
|
| Leuprolide | 2 | 2009 | 7 | 0.170 |
Why?
|
| Histone Deacetylases | 1 | 2019 | 8 | 0.160 |
Why?
|
| Early Diagnosis | 1 | 2019 | 62 | 0.160 |
Why?
|
| HMGB Proteins | 1 | 2018 | 1 | 0.160 |
Why?
|
| SOXF Transcription Factors | 1 | 2018 | 4 | 0.160 |
Why?
|
| Exosomes | 1 | 2019 | 43 | 0.160 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 2 | 2017 | 23 | 0.160 |
Why?
|
| Inflammation Mediators | 2 | 2017 | 104 | 0.160 |
Why?
|
| Phosphorylation | 2 | 2016 | 229 | 0.160 |
Why?
|
| Dyspareunia | 1 | 2018 | 7 | 0.160 |
Why?
|
| Informed Consent | 1 | 2018 | 34 | 0.160 |
Why?
|
| Adrenomedullin | 1 | 2018 | 4 | 0.160 |
Why?
|
| Species Specificity | 2 | 2017 | 90 | 0.160 |
Why?
|
| In Situ Nick-End Labeling | 3 | 2005 | 12 | 0.160 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 2 | 2020 | 46 | 0.160 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2018 | 14 | 0.160 |
Why?
|
| Granulocytes | 1 | 2018 | 12 | 0.160 |
Why?
|
| Neovascularization, Physiologic | 1 | 1999 | 110 | 0.150 |
Why?
|
| Immunoglobulin J Recombination Signal Sequence-Binding Protein | 1 | 2018 | 2 | 0.150 |
Why?
|
| Neoplasm Invasiveness | 1 | 1999 | 190 | 0.150 |
Why?
|
| Fallopian Tubes | 3 | 2003 | 9 | 0.150 |
Why?
|
| Complement Activation | 1 | 2017 | 9 | 0.150 |
Why?
|
| Neoplasm Metastasis | 1 | 1999 | 220 | 0.150 |
Why?
|
| Choice Behavior | 1 | 2018 | 87 | 0.150 |
Why?
|
| Tristetraprolin | 1 | 2017 | 2 | 0.150 |
Why?
|
| Models, Immunological | 1 | 2017 | 9 | 0.150 |
Why?
|
| Regression Analysis | 5 | 2001 | 293 | 0.150 |
Why?
|
| L-Selectin | 2 | 2007 | 3 | 0.150 |
Why?
|
| Chemokines | 2 | 2018 | 35 | 0.150 |
Why?
|
| Observer Variation | 5 | 2013 | 105 | 0.150 |
Why?
|
| Tacrolimus Binding Proteins | 1 | 2017 | 4 | 0.140 |
Why?
|
| Treatment Failure | 1 | 2017 | 162 | 0.140 |
Why?
|
| Antibodies, Monoclonal | 6 | 2001 | 246 | 0.140 |
Why?
|
| Recurrence | 1 | 2017 | 263 | 0.140 |
Why?
|
| Decision Making | 1 | 2018 | 195 | 0.140 |
Why?
|
| Rabbits | 5 | 2003 | 197 | 0.140 |
Why?
|
| Mucin-1 | 2 | 2014 | 13 | 0.140 |
Why?
|
| Contraception, Immunologic | 1 | 1996 | 1 | 0.140 |
Why?
|
| Regeneration | 1 | 2018 | 170 | 0.140 |
Why?
|
| Contraceptives, Oral | 1 | 1996 | 23 | 0.130 |
Why?
|
| Follicular Phase | 2 | 2015 | 11 | 0.130 |
Why?
|
| Ultrasonography | 3 | 2011 | 379 | 0.130 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2016 | 19 | 0.130 |
Why?
|
| Ki-67 Antigen | 2 | 2014 | 30 | 0.130 |
Why?
|
| Interleukin-17 | 1 | 2015 | 26 | 0.130 |
Why?
|
| Nuclear Proteins | 1 | 2015 | 75 | 0.130 |
Why?
|
| Selectins | 2 | 2010 | 3 | 0.120 |
Why?
|
| Nerve Tissue Proteins | 1 | 2016 | 120 | 0.120 |
Why?
|
| Cleavage Stage, Ovum | 1 | 1994 | 1 | 0.120 |
Why?
|
| Nuclear Receptor Coactivators | 1 | 2014 | 1 | 0.120 |
Why?
|
| Specimen Handling | 1 | 1994 | 33 | 0.120 |
Why?
|
| Urinalysis | 1 | 2014 | 27 | 0.120 |
Why?
|
| Ovarian Follicle | 1 | 1994 | 30 | 0.120 |
Why?
|
| Chemokine CXCL13 | 1 | 2014 | 2 | 0.120 |
Why?
|
| Germany | 1 | 2014 | 6 | 0.120 |
Why?
|
| Interferon Regulatory Factors | 1 | 2014 | 13 | 0.120 |
Why?
|
| CA-125 Antigen | 1 | 2014 | 7 | 0.120 |
Why?
|
| Area Under Curve | 1 | 2014 | 93 | 0.120 |
Why?
|
| Cell Differentiation | 4 | 2002 | 469 | 0.120 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 1995 | 92 | 0.120 |
Why?
|
| ROC Curve | 1 | 2014 | 164 | 0.120 |
Why?
|
| Cytochrome P-450 CYP1A1 | 1 | 2014 | 6 | 0.120 |
Why?
|
| Ovariectomy | 2 | 2014 | 166 | 0.120 |
Why?
|
| Keratins | 2 | 2006 | 39 | 0.120 |
Why?
|
| Predictive Value of Tests | 2 | 2014 | 876 | 0.120 |
Why?
|
| COUP Transcription Factor II | 1 | 2013 | 1 | 0.120 |
Why?
|
| Systems Biology | 1 | 2013 | 10 | 0.110 |
Why?
|
| Postural Balance | 1 | 2016 | 182 | 0.110 |
Why?
|
| Collagen | 5 | 2019 | 225 | 0.110 |
Why?
|
| Phenotype | 3 | 2020 | 632 | 0.110 |
Why?
|
| Pathology, Clinical | 1 | 2013 | 13 | 0.110 |
Why?
|
| Guidelines as Topic | 1 | 2013 | 47 | 0.110 |
Why?
|
| beta Catenin | 1 | 2013 | 37 | 0.110 |
Why?
|
| Extracellular Matrix Proteins | 2 | 2004 | 45 | 0.110 |
Why?
|
| Principal Component Analysis | 2 | 2011 | 68 | 0.110 |
Why?
|
| Blastocyst | 3 | 2002 | 11 | 0.110 |
Why?
|
| Pregnancy Maintenance | 1 | 2013 | 1 | 0.110 |
Why?
|
| Embryo Loss | 1 | 2013 | 2 | 0.110 |
Why?
|
| Pesticides | 1 | 2016 | 199 | 0.110 |
Why?
|
| North Carolina | 2 | 2016 | 1514 | 0.110 |
Why?
|
| Peritoneal Cavity | 1 | 2012 | 6 | 0.110 |
Why?
|
| Immunomodulation | 1 | 2013 | 32 | 0.110 |
Why?
|
| Occupational Exposure | 1 | 2016 | 232 | 0.110 |
Why?
|
| Interleukin-1beta | 2 | 2015 | 42 | 0.110 |
Why?
|
| Genomics | 1 | 2013 | 85 | 0.110 |
Why?
|
| Mifepristone | 4 | 2004 | 8 | 0.110 |
Why?
|
| Transients and Migrants | 1 | 2016 | 290 | 0.110 |
Why?
|
| Emigrants and Immigrants | 1 | 2016 | 244 | 0.110 |
Why?
|
| Birth Rate | 1 | 2012 | 2 | 0.100 |
Why?
|
| Smoking | 1 | 2016 | 497 | 0.100 |
Why?
|
| Thyrotropin | 1 | 2011 | 8 | 0.100 |
Why?
|
| Prolactin | 1 | 2011 | 10 | 0.100 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2009 | 67 | 0.100 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2013 | 226 | 0.100 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2011 | 35 | 0.100 |
Why?
|
| Fluorescent Antibody Technique | 3 | 2013 | 91 | 0.100 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2012 | 85 | 0.100 |
Why?
|
| Androgens | 2 | 2002 | 30 | 0.100 |
Why?
|
| Chronic Disease | 1 | 2012 | 406 | 0.090 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2009 | 73 | 0.090 |
Why?
|
| Plasmids | 2 | 2020 | 48 | 0.090 |
Why?
|
| Mice, Inbred Strains | 2 | 2000 | 48 | 0.090 |
Why?
|
| RNA | 3 | 2016 | 92 | 0.090 |
Why?
|
| Analysis of Variance | 1 | 2011 | 463 | 0.090 |
Why?
|
| Apolipoprotein A-I | 1 | 2009 | 68 | 0.090 |
Why?
|
| Hispanic Americans | 1 | 2016 | 940 | 0.080 |
Why?
|
| Pelvic Neoplasms | 1 | 1989 | 2 | 0.080 |
Why?
|
| Sensitivity and Specificity | 3 | 2001 | 582 | 0.080 |
Why?
|
| Double-Blind Method | 3 | 2018 | 525 | 0.080 |
Why?
|
| Growth Inhibitors | 2 | 2000 | 10 | 0.080 |
Why?
|
| Lymphokines | 2 | 2000 | 13 | 0.080 |
Why?
|
| Pregnancy, Ectopic | 1 | 2008 | 8 | 0.080 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2008 | 115 | 0.080 |
Why?
|
| Hormone Antagonists | 2 | 1999 | 5 | 0.080 |
Why?
|
| Vitronectin | 3 | 1999 | 6 | 0.080 |
Why?
|
| Tissue Distribution | 3 | 2002 | 61 | 0.080 |
Why?
|
| Plant Extracts | 1 | 2008 | 61 | 0.080 |
Why?
|
| Integrin alpha4 | 2 | 2000 | 2 | 0.080 |
Why?
|
| Cell Movement | 2 | 2018 | 169 | 0.080 |
Why?
|
| Cysteine-Rich Protein 61 | 1 | 2007 | 2 | 0.070 |
Why?
|
| Nuclear Receptor Coactivator 1 | 2 | 2009 | 4 | 0.070 |
Why?
|
| Breast Neoplasms | 3 | 1983 | 765 | 0.070 |
Why?
|
| Histone Acetyltransferases | 2 | 2009 | 7 | 0.070 |
Why?
|
| Hot Flashes | 2 | 2018 | 48 | 0.070 |
Why?
|
| Autoantibodies | 1 | 2007 | 49 | 0.070 |
Why?
|
| Prevalence | 1 | 2010 | 981 | 0.070 |
Why?
|
| Laminin | 3 | 2002 | 16 | 0.070 |
Why?
|
| Interleukin-8 | 2 | 2017 | 26 | 0.070 |
Why?
|
| Receptors, Collagen | 2 | 1997 | 2 | 0.070 |
Why?
|
| Mucins | 1 | 2006 | 18 | 0.070 |
Why?
|
| Multigene Family | 4 | 2014 | 51 | 0.070 |
Why?
|
| Flow Cytometry | 2 | 1997 | 185 | 0.070 |
Why?
|
| Integrin alpha1beta1 | 2 | 1996 | 2 | 0.070 |
Why?
|
| Receptors, Cytokine | 2 | 2016 | 8 | 0.070 |
Why?
|
| Karyotyping | 1 | 2006 | 29 | 0.070 |
Why?
|
| Binding, Competitive | 1 | 2006 | 33 | 0.070 |
Why?
|
| Estrogen Receptor beta | 1 | 2006 | 13 | 0.070 |
Why?
|
| Integrin alpha4beta1 | 2 | 1996 | 4 | 0.070 |
Why?
|
| Metalloproteases | 1 | 2006 | 4 | 0.070 |
Why?
|
| Amino Acid Sequence | 3 | 2004 | 285 | 0.070 |
Why?
|
| Molecular Sequence Data | 3 | 2004 | 359 | 0.070 |
Why?
|
| Pregnancy, Multiple | 1 | 2005 | 10 | 0.070 |
Why?
|
| Choristoma | 2 | 2017 | 17 | 0.070 |
Why?
|
| Ligands | 3 | 2006 | 81 | 0.070 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2006 | 36 | 0.070 |
Why?
|
| Uterine Neoplasms | 3 | 2007 | 27 | 0.060 |
Why?
|
| Male | 6 | 2016 | 19165 | 0.060 |
Why?
|
| DNA Fragmentation | 1 | 2005 | 7 | 0.060 |
Why?
|
| bcl-X Protein | 1 | 2005 | 5 | 0.060 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2005 | 15 | 0.060 |
Why?
|
| Mice, Mutant Strains | 2 | 2015 | 52 | 0.060 |
Why?
|
| Estrous Cycle | 1 | 2004 | 3 | 0.060 |
Why?
|
| Proteoglycans | 2 | 2002 | 32 | 0.060 |
Why?
|
| Culture Media | 2 | 2002 | 47 | 0.060 |
Why?
|
| Calcium-Binding Proteins | 1 | 2004 | 45 | 0.060 |
Why?
|
| Drug Combinations | 2 | 2002 | 98 | 0.060 |
Why?
|
| RNA, Small Interfering | 2 | 2016 | 114 | 0.060 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2004 | 12 | 0.060 |
Why?
|
| Matrix Metalloproteinases | 2 | 2005 | 11 | 0.060 |
Why?
|
| Zebrafish Proteins | 1 | 2003 | 3 | 0.060 |
Why?
|
| Protein Isoforms | 1 | 2003 | 57 | 0.060 |
Why?
|
| Peptides | 2 | 2003 | 120 | 0.060 |
Why?
|
| Isoflavones | 1 | 2003 | 81 | 0.050 |
Why?
|
| Soybean Proteins | 1 | 2003 | 74 | 0.050 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2003 | 85 | 0.050 |
Why?
|
| Promegestone | 5 | 1983 | 5 | 0.050 |
Why?
|
| Aged | 3 | 2016 | 10301 | 0.050 |
Why?
|
| Receptors, Leukotriene B4 | 1 | 2002 | 1 | 0.050 |
Why?
|
| Receptors, Prostaglandin | 1 | 2002 | 3 | 0.050 |
Why?
|
| Growth Substances | 1 | 2002 | 8 | 0.050 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2002 | 36 | 0.050 |
Why?
|
| Nuclear Receptor Coactivator 2 | 1 | 2002 | 3 | 0.050 |
Why?
|
| Nuclear Receptor Coactivator 3 | 1 | 2002 | 3 | 0.050 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2002 | 7 | 0.050 |
Why?
|
| Receptors, Cell Surface | 1 | 2002 | 70 | 0.050 |
Why?
|
| Cross-Sectional Studies | 2 | 2018 | 1531 | 0.050 |
Why?
|
| Nitric Oxide | 1 | 2002 | 111 | 0.050 |
Why?
|
| Cluster Analysis | 2 | 2016 | 125 | 0.050 |
Why?
|
| Cell Communication | 1 | 2002 | 32 | 0.050 |
Why?
|
| Gravidity | 1 | 2001 | 3 | 0.050 |
Why?
|
| Parity | 1 | 2001 | 20 | 0.050 |
Why?
|
| Iodoacetates | 1 | 1981 | 1 | 0.050 |
Why?
|
| Endothelium, Vascular | 1 | 2002 | 156 | 0.050 |
Why?
|
| Iodoacetamide | 1 | 1981 | 8 | 0.050 |
Why?
|
| Fluoroimmunoassay | 1 | 2001 | 2 | 0.050 |
Why?
|
| Vimentin | 1 | 2001 | 10 | 0.050 |
Why?
|
| Morphogenesis | 1 | 2001 | 9 | 0.050 |
Why?
|
| Drug Administration Schedule | 2 | 2018 | 276 | 0.050 |
Why?
|
| Cytoskeletal Proteins | 1 | 2001 | 15 | 0.050 |
Why?
|
| Australia | 1 | 2021 | 72 | 0.050 |
Why?
|
| Postmenopause | 1 | 2003 | 430 | 0.050 |
Why?
|
| Metribolone | 1 | 2000 | 2 | 0.050 |
Why?
|
| Dihydrotestosterone | 1 | 2000 | 4 | 0.050 |
Why?
|
| Receptors, LHRH | 1 | 2020 | 1 | 0.050 |
Why?
|
| Macromolecular Substances | 2 | 1995 | 17 | 0.050 |
Why?
|
| Left-Right Determination Factors | 1 | 2000 | 1 | 0.050 |
Why?
|
| Mammals | 1 | 2000 | 12 | 0.050 |
Why?
|
| Polymerase Chain Reaction | 1 | 2001 | 198 | 0.050 |
Why?
|
| Reproductive Techniques | 1 | 2000 | 2 | 0.050 |
Why?
|
| Lentivirus | 1 | 2020 | 11 | 0.050 |
Why?
|
| Lipids | 2 | 2017 | 232 | 0.050 |
Why?
|
| Serum Albumin, Bovine | 1 | 2000 | 10 | 0.050 |
Why?
|
| Platelet Membrane Glycoproteins | 1 | 2000 | 7 | 0.040 |
Why?
|
| Urinary Bladder Diseases | 1 | 2020 | 21 | 0.040 |
Why?
|
| Maternal Age | 1 | 2000 | 15 | 0.040 |
Why?
|
| Genital Neoplasms, Female | 1 | 2020 | 17 | 0.040 |
Why?
|
| Neutrophil Infiltration | 1 | 2019 | 13 | 0.040 |
Why?
|
| Transfection | 1 | 2000 | 191 | 0.040 |
Why?
|
| Autocrine Communication | 1 | 2019 | 7 | 0.040 |
Why?
|
| Integrin beta4 | 1 | 1999 | 1 | 0.040 |
Why?
|
| Integrin alpha6 | 1 | 1999 | 4 | 0.040 |
Why?
|
| Relaxin | 1 | 1999 | 4 | 0.040 |
Why?
|
| Genetic Vectors | 1 | 2020 | 120 | 0.040 |
Why?
|
| Peritoneum | 1 | 2019 | 33 | 0.040 |
Why?
|
| Continental Population Groups | 1 | 2001 | 237 | 0.040 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2019 | 32 | 0.040 |
Why?
|
| Colonic Neoplasms | 1 | 2020 | 71 | 0.040 |
Why?
|
| Immunosuppressive Agents | 1 | 2001 | 240 | 0.040 |
Why?
|
| Tenascin | 1 | 1999 | 5 | 0.040 |
Why?
|
| GATA2 Transcription Factor | 1 | 2018 | 1 | 0.040 |
Why?
|
| Hepatocyte Nuclear Factor 3-beta | 1 | 2018 | 1 | 0.040 |
Why?
|
| Cell Polarity | 1 | 2018 | 16 | 0.040 |
Why?
|
| Hedgehog Proteins | 1 | 2018 | 9 | 0.040 |
Why?
|
| Levonorgestrel | 1 | 1998 | 4 | 0.040 |
Why?
|
| Indazoles | 1 | 2018 | 1 | 0.040 |
Why?
|
| Pyridones | 1 | 2018 | 10 | 0.040 |
Why?
|
| Embryonic and Fetal Development | 1 | 1998 | 12 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2009 | 153 | 0.040 |
Why?
|
| DNA Fingerprinting | 2 | 2012 | 6 | 0.040 |
Why?
|
| Blood Chemical Analysis | 1 | 2018 | 22 | 0.040 |
Why?
|
| Protein Precursors | 1 | 2018 | 22 | 0.040 |
Why?
|
| Corpus Luteum | 1 | 1998 | 4 | 0.040 |
Why?
|
| Receptors, Interleukin-8B | 1 | 2018 | 6 | 0.040 |
Why?
|
| Arginase | 1 | 2018 | 6 | 0.040 |
Why?
|
| Ovary | 1 | 1998 | 58 | 0.040 |
Why?
|
| Hysterectomy | 2 | 2016 | 46 | 0.040 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2009 | 71 | 0.040 |
Why?
|
| Postpartum Period | 1 | 2018 | 33 | 0.040 |
Why?
|
| Logistic Models | 1 | 2000 | 781 | 0.040 |
Why?
|
| Choriocarcinoma | 1 | 2017 | 1 | 0.040 |
Why?
|
| Enzyme Inhibitors | 1 | 2018 | 166 | 0.040 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 1997 | 14 | 0.040 |
Why?
|
| Protein Transport | 1 | 2017 | 74 | 0.040 |
Why?
|
| Gene Silencing | 1 | 2017 | 48 | 0.040 |
Why?
|
| Reactive Oxygen Species | 1 | 2018 | 157 | 0.040 |
Why?
|
| Receptors, Laminin | 1 | 1997 | 1 | 0.040 |
Why?
|
| Integrin alpha6beta4 | 1 | 1997 | 1 | 0.040 |
Why?
|
| Integrin alpha3beta1 | 1 | 1997 | 1 | 0.040 |
Why?
|
| Immunosorbent Techniques | 1 | 1997 | 2 | 0.040 |
Why?
|
| Mice, Inbred BALB C | 1 | 2017 | 167 | 0.040 |
Why?
|
| Premenopause | 1 | 2017 | 44 | 0.040 |
Why?
|
| Immunoglobulins | 1 | 1997 | 15 | 0.040 |
Why?
|
| Antigens, Surface | 1 | 1997 | 24 | 0.040 |
Why?
|
| Cadherins | 1 | 1997 | 26 | 0.040 |
Why?
|
| Biological Assay | 1 | 1996 | 19 | 0.040 |
Why?
|
| Dogs | 3 | 1981 | 120 | 0.030 |
Why?
|
| RNA, Neoplasm | 1 | 1996 | 20 | 0.030 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2016 | 16 | 0.030 |
Why?
|
| Hospitals, Teaching | 1 | 2016 | 31 | 0.030 |
Why?
|
| Chemotaxis | 1 | 2016 | 24 | 0.030 |
Why?
|
| Oocyte Retrieval | 1 | 2016 | 2 | 0.030 |
Why?
|
| Protein Biosynthesis | 1 | 1996 | 40 | 0.030 |
Why?
|
| Genetic Markers | 1 | 2016 | 124 | 0.030 |
Why?
|
| Macrophages | 1 | 2018 | 191 | 0.030 |
Why?
|
| Patient Selection | 1 | 1998 | 276 | 0.030 |
Why?
|
| Stem Cells | 1 | 2019 | 313 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2016 | 36 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2016 | 43 | 0.030 |
Why?
|
| Lymphocyte Activation | 1 | 2016 | 88 | 0.030 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2015 | 29 | 0.030 |
Why?
|
| Papio anubis | 1 | 2015 | 8 | 0.030 |
Why?
|
| Chemokine CX3CL1 | 1 | 2015 | 3 | 0.030 |
Why?
|
| Hela Cells | 1 | 2015 | 79 | 0.030 |
Why?
|
| Chemokine CXCL1 | 1 | 2015 | 16 | 0.030 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2015 | 24 | 0.030 |
Why?
|
| Chemokine CXCL12 | 1 | 2015 | 25 | 0.030 |
Why?
|
| Bone Density | 1 | 2017 | 205 | 0.030 |
Why?
|
| Integrin alpha1 | 1 | 1995 | 1 | 0.030 |
Why?
|
| alpha-Macroglobulins | 1 | 1995 | 3 | 0.030 |
Why?
|
| Pyrophosphatases | 1 | 2015 | 3 | 0.030 |
Why?
|
| Microdissection | 1 | 2015 | 3 | 0.030 |
Why?
|
| Phosphoric Diester Hydrolases | 1 | 2015 | 10 | 0.030 |
Why?
|
| Chromatography, Liquid | 1 | 2015 | 43 | 0.030 |
Why?
|
| Microarray Analysis | 1 | 2014 | 19 | 0.030 |
Why?
|
| Monkey Diseases | 1 | 2014 | 20 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2015 | 112 | 0.030 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2015 | 60 | 0.030 |
Why?
|
| Extracellular Matrix | 1 | 1997 | 245 | 0.030 |
Why?
|
| Pregnancy Trimester, First | 1 | 1994 | 9 | 0.030 |
Why?
|
| Receptors, Cytoadhesin | 1 | 1994 | 1 | 0.030 |
Why?
|
| Tissue Donors | 1 | 2016 | 198 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 1995 | 203 | 0.030 |
Why?
|
| Age Factors | 1 | 1998 | 1188 | 0.030 |
Why?
|
| Natural Cytotoxicity Triggering Receptor 1 | 1 | 2014 | 1 | 0.030 |
Why?
|
| Receptors, IgG | 1 | 2014 | 7 | 0.030 |
Why?
|
| Quality of Life | 1 | 2020 | 946 | 0.030 |
Why?
|
| Receptors, Complement | 1 | 1994 | 1 | 0.030 |
Why?
|
| Complement C3 | 1 | 1994 | 9 | 0.030 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2013 | 21 | 0.030 |
Why?
|
| Gonadal Steroid Hormones | 1 | 1994 | 34 | 0.030 |
Why?
|
| Binding Sites | 1 | 2013 | 130 | 0.030 |
Why?
|
| Metabolomics | 1 | 2013 | 54 | 0.030 |
Why?
|
| Administration, Cutaneous | 2 | 2008 | 116 | 0.030 |
Why?
|
| Genome, Human | 1 | 2013 | 132 | 0.030 |
Why?
|
| Macaca mulatta | 1 | 2014 | 305 | 0.030 |
Why?
|
| Cytosol | 3 | 1982 | 25 | 0.030 |
Why?
|
| Prognosis | 1 | 2017 | 1497 | 0.030 |
Why?
|
| Tissue Banks | 1 | 2012 | 15 | 0.030 |
Why?
|
| Medroxyprogesterone | 1 | 1991 | 14 | 0.030 |
Why?
|
| Algorithms | 2 | 2005 | 495 | 0.020 |
Why?
|
| Membrane Glycoproteins | 2 | 2006 | 101 | 0.020 |
Why?
|
| Radioligand Assay | 2 | 1981 | 20 | 0.020 |
Why?
|
| Immunoproteins | 1 | 2009 | 1 | 0.020 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2009 | 11 | 0.020 |
Why?
|
| Mass Spectrometry | 1 | 2009 | 102 | 0.020 |
Why?
|
| Fibrinogen | 1 | 2009 | 44 | 0.020 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2009 | 40 | 0.020 |
Why?
|
| Heat-Shock Proteins | 1 | 2009 | 34 | 0.020 |
Why?
|
| Fluorescent Dyes | 1 | 2009 | 48 | 0.020 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2009 | 78 | 0.020 |
Why?
|
| Microscopy, Phase-Contrast | 1 | 1988 | 12 | 0.020 |
Why?
|
| Organ Specificity | 2 | 1996 | 81 | 0.020 |
Why?
|
| Histocytochemistry | 1 | 1988 | 31 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 2009 | 136 | 0.020 |
Why?
|
| Microscopy, Immunoelectron | 1 | 2007 | 4 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2007 | 51 | 0.020 |
Why?
|
| Organ Size | 1 | 2008 | 218 | 0.020 |
Why?
|
| Cyclic AMP | 1 | 2007 | 46 | 0.020 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2007 | 27 | 0.020 |
Why?
|
| Leiomyoma | 1 | 2007 | 16 | 0.020 |
Why?
|
| Forkhead Transcription Factors | 1 | 2007 | 27 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 1995 | 3990 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2006 | 33 | 0.020 |
Why?
|
| Antibodies | 1 | 2006 | 52 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 1991 | 608 | 0.020 |
Why?
|
| Matrix Metalloproteinase 3 | 1 | 2006 | 6 | 0.020 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2006 | 14 | 0.020 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2006 | 7 | 0.020 |
Why?
|
| Interleukin-1 | 1 | 2006 | 33 | 0.020 |
Why?
|
| Genome | 1 | 2005 | 38 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2005 | 130 | 0.020 |
Why?
|
| Kinetics | 2 | 1982 | 209 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2007 | 881 | 0.010 |
Why?
|
| Base Sequence | 1 | 2004 | 252 | 0.010 |
Why?
|
| Bone Remodeling | 1 | 2003 | 9 | 0.010 |
Why?
|
| Wnt2 Protein | 1 | 2003 | 1 | 0.010 |
Why?
|
| Wnt Proteins | 1 | 2003 | 18 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2007 | 835 | 0.010 |
Why?
|
| Collagen Type I | 1 | 2003 | 42 | 0.010 |
Why?
|
| Chromatography, DEAE-Cellulose | 1 | 1983 | 3 | 0.010 |
Why?
|
| Photochemistry | 1 | 1983 | 7 | 0.010 |
Why?
|
| Centrifugation, Density Gradient | 1 | 1983 | 11 | 0.010 |
Why?
|
| Chromatography, Gel | 1 | 1983 | 9 | 0.010 |
Why?
|
| Affinity Labels | 1 | 1983 | 3 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2003 | 293 | 0.010 |
Why?
|
| Nafoxidine | 1 | 1982 | 1 | 0.010 |
Why?
|
| Bromodeoxyuridine | 1 | 1982 | 7 | 0.010 |
Why?
|
| Cycloheximide | 1 | 1982 | 9 | 0.010 |
Why?
|
| Butyrates | 1 | 1982 | 3 | 0.010 |
Why?
|
| Tissue Extracts | 1 | 2002 | 2 | 0.010 |
Why?
|
| Cytoplasm | 1 | 1982 | 29 | 0.010 |
Why?
|
| Basement Membrane | 1 | 2002 | 8 | 0.010 |
Why?
|
| Cell Membrane | 1 | 2002 | 96 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2003 | 545 | 0.010 |
Why?
|
| Castration | 1 | 1981 | 1 | 0.010 |
Why?
|
| Potassium Chloride | 1 | 1981 | 5 | 0.010 |
Why?
|
| Horseradish Peroxidase | 1 | 2001 | 5 | 0.010 |
Why?
|
| Radioimmunoassay | 1 | 2001 | 25 | 0.010 |
Why?
|
| False Positive Reactions | 1 | 2001 | 29 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2005 | 1817 | 0.010 |
Why?
|
| Quality Control | 1 | 2001 | 44 | 0.010 |
Why?
|
| Muridae | 1 | 2000 | 2 | 0.010 |
Why?
|
| Guinea Pigs | 1 | 2000 | 11 | 0.010 |
Why?
|
| Temperature | 1 | 1980 | 55 | 0.010 |
Why?
|
| Rats | 1 | 2004 | 1595 | 0.010 |
Why?
|
| Fibronectins | 1 | 1999 | 36 | 0.010 |
Why?
|
| Ethinyl Estradiol-Norgestrel Combination | 1 | 1998 | 4 | 0.010 |
Why?
|
| Ethinyl Estradiol | 1 | 1998 | 9 | 0.010 |
Why?
|
| Macaca fascicularis | 1 | 1998 | 434 | 0.010 |
Why?
|
| Receptors, OSM-LIF | 1 | 1996 | 1 | 0.010 |
Why?
|
| Leukemia Inhibitory Factor Receptor alpha Subunit | 1 | 1996 | 1 | 0.010 |
Why?
|
| Cross-Over Studies | 1 | 1996 | 95 | 0.010 |
Why?
|
| Administration, Oral | 1 | 1996 | 187 | 0.010 |
Why?
|
| Precipitin Tests | 1 | 1995 | 14 | 0.010 |
Why?
|
| Peptide Fragments | 1 | 1998 | 399 | 0.010 |
Why?
|
| Complement Factor B | 1 | 1994 | 1 | 0.010 |
Why?
|
| Macrophage-1 Antigen | 1 | 1994 | 2 | 0.010 |
Why?
|
| Complement Inactivator Proteins | 1 | 1994 | 3 | 0.010 |
Why?
|
| Receptors, Complement 3b | 1 | 1994 | 8 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1994 | 36 | 0.010 |
Why?
|
| Receptors, Complement 3d | 1 | 1994 | 12 | 0.010 |
Why?
|
| Injections, Intramuscular | 1 | 1991 | 43 | 0.010 |
Why?
|
| Medroxyprogesterone Acetate | 1 | 1991 | 102 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 1991 | 367 | 0.010 |
Why?
|